Home
Technology
Drug Delivery Platform
Sensitive DNA/RNA Synthesis Platform
Products & Services
COVID-19 Research Support
COVID-19 mRNA Vaccine Development Services
Custom Oligo Synthesis Services For COVID-19 Research
Liposomes Drug Delivery Services For COVID-19
Oligo Synthesis Service
Antisense Oligonucleotides Synthesis
CpG oligonucleotides (CpG ODN)
Custom BNA Oligonucleotide Synthesis
Custom DNA Oligonucleotides Synthesis
Custom LNA Synthesis
Custom mRNA Synthesis
Custom Oligo Synthesis
Custom RNA Oligonucleotides Synthesis
Diagnostic Probes & Oligos
DNA/RNA Modification
GMP Oligonucleotide Manufacturing Services
Long Oligonucleotide Synthesis
Oligo Modifications
Oligonucleotide Conjugation Services
RNA Interference Services (RNAi)
Predesigned siRNA
RNAi Stable Cell Line Screening Services
RNAi Transfection Optimization Services
shRNA Vector Construction Services
siRNA Interference Detection Services
siRNA Synthesis Services
tRNA Products & Services
DNA/RNA Synthesis Reagents
CPGs for oligo synthesis
Dye Phosphoramidites
Label Phosphoramidites
Linker Phosphoramidites
RNA Phosphoramidites
Sensitive DNA/RNA Synthesis
Spacer Phosphoramidites
Oligo Analysis & Purification
siRNA Products & Services
lncRNA research
Predesigned siRNA Library
shRNA plasmid expression vector
siRNA Products
siRNA Screening Services
Custom siRNA
Custom Chemically Modified siRNA
Custom Fluorescence-labeled siRNA
siRNA Control
siRNA Sets
Drug Delivery System
Exosome
Liposomes
GalNAc-siRNA Conjugates
Antibody-siRNA Conjugates
Peptide-siRNA conjugates
Polymer-siRNA Conjugates
Cholesterol-siRNA Conjugates
Nanoparticle-siRNA Conjugates
Aptamer-siRNA conjugates
Folic acid–siRNA conjugates
CpG-siRNA Conjugates
Dynamic Polyconjugates (DPC)
Professional Support for mRNA Vaccines
Lipid Nanoparticle
Support
FAQs
FAQs of siRNA
News
Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)
Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition
FDA approves first RNAi treatment for inherited rare diseases
mRNA-1647,the first infectious disease mRNA vaccine to enter the second phase of research
Onpattro, The First FDA-approved RNAi Drug
Resources
Bioinformatics Online Tools
Explore & Learn
Webinar
Webinar: Naturally Occurring Sensitive Nucleic Acids, Applications and Chemical Synthesis
Webinar: Viral RNA Modifications and Implications for Novel Therapeutics
Events
Aptamers 2022
CPhI North America
Oligo 2022 Oxford: Antisense & Therapeutic Nucleic Acids
TIDES USA: Oligonucleotide & Peptide Therapeutics Conference
Ordering
About Us
Contact Us
Careers
Home
Products & Services
siRNA Products & Services
siRNA Products
siRNA Products
siRNA Products
Patisiran Sodium
BRC-002
CAS:
1386913-72-9
Lumasiran
BRC-003
CAS:
1834610-13-7
Vutrisiran
BRC-004
CAS:
1867157-35-4
Cemdisiran
BRC-005
CAS:
1639264-46-2
Molecular Formula:
C542H711F17N169O330P45S6
Molecular Weight:
16782.53
Fitusiran
BRC-006
CAS:
1499251-18-1
SLN124
BRC-007
Zerlasiran
BRC-008
Molecular Formula:
C443H594N144O277P40S10
Molecular Weight:
14155.81
Lumasiran sodium
BRC-009
CAS:
1834612-06-4
Elebsiran
BRC-010
CAS:
2648009-64-5
Molecular Formula:
C485H658F9N158O294P39S6
Molecular Weight:
14976.62
Fazirsiran
BRC-011
CAS:
2175009-08-0
Revusiran
BRC-012
CAS:
1438322-82-7
Manusiran
BRC-013
CAS:
2646704-10-9
Molecular Formula:
C434H570F19N145O270P40S10
Molecular Weight:
14058.53
*
Only for research. Not suitable for any diagnostic or therapeutic use.
CONTACT US
Call us at:
International:
UK:
US & Canada (Toll free):
Email:
Fax:
Event information
Aptamers 2022
April 4-5, 2022
Oxford, UK
Oligo 2022 Oxford: Antisense & Therapeutic Nucleic Acids
April 6-7, 2022
St Hilda's College, Oxford, UK
Inquiry Basket
Loading ......
Delete selected
Go to checkout